Does the media favor RPRX or CRNX?

In the previous week, Crinetics Pharmaceuticals had 3 more articles in the media than Royalty Pharma. MarketBeat recorded 10 mentions for Crinetics Pharmaceuticals and 7 mentions for Royalty Pharma. Crinetics Pharmaceuticals' average media sentiment score of 1.56 beat Royalty Pharma's score of 0.80 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Crinetics Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor ZTS or CRNX?

In the previous week, Zoetis had 3 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 13 mentions for Zoetis and 10 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 1.56 beat Zoetis' score of 1.08 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zoetis 9 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Crinetics Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor VTRS or CRNX?

In the previous week, Crinetics Pharmaceuticals had 8 more articles in the media than Viatris. MarketBeat recorded 10 mentions for Crinetics Pharmaceuticals and 2 mentions for Viatris. Crinetics Pharmaceuticals' average media sentiment score of 1.56 beat Viatris' score of 1.15 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Crinetics Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to JAZZ or CRNX?

In the previous week, Jazz Pharmaceuticals had 32 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 42 mentions for Jazz Pharmaceuticals and 10 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 1.56 beat Jazz Pharmaceuticals' score of 0.35 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 11 Very Positive mention(s) 9 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Crinetics Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor NBIX or CRNX?

In the previous week, Neurocrine Biosciences had 11 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 21 mentions for Neurocrine Biosciences and 10 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 1.56 beat Neurocrine Biosciences' score of 1.34 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 18 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Crinetics Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Crinetics Pharmaceuticals (CRNX) Competitors

$84.84 -0.01 (-0.01%)

As of 08/28/2026 04:00 PM Eastern

Compare

CRNX vs. RPRX, ZTS, VTRS, JAZZ, and NBIX

Should you buy Crinetics Pharmaceuticals stock or one of its competitors? Crinetics Pharmaceuticals's main competitors and comparable companies include Royalty Pharma (RPRX), Zoetis (ZTS), Viatris (VTRS), Jazz Pharmaceuticals (JAZZ), and Neurocrine Biosciences (NBIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Crinetics Pharmaceuticals compare to Royalty Pharma?

Royalty Pharma (NASDAQ:RPRX) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

Royalty Pharma has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.38B	14.71	$770.95M	$1.45	41.97
Crinetics Pharmaceuticals	$7.70M	1,168.70	-$465.32M	-$5.04	N/A

Royalty Pharma has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.12, meaning that its stock price is 88% less volatile than the broader market.

Royalty Pharma has a net margin of 32.14% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Royalty Pharma's return on equity of 30.01% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	32.14%	30.01%	14.91%
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

Royalty Pharma presently has a consensus target price of $60.86, suggesting a potential upside of 0.01%. Crinetics Pharmaceuticals has a consensus target price of $81.00, suggesting a potential downside of 4.53%. Given Royalty Pharma's stronger consensus rating and higher probable upside, research analysts plainly believe Royalty Pharma is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24

In the previous week, Crinetics Pharmaceuticals had 3 more articles in the media than Royalty Pharma. MarketBeat recorded 10 mentions for Crinetics Pharmaceuticals and 7 mentions for Royalty Pharma. Crinetics Pharmaceuticals' average media sentiment score of 1.56 beat Royalty Pharma's score of 0.80 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Crinetics Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

54.4% of Royalty Pharma shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 18.8% of Royalty Pharma shares are held by insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Royalty Pharma beats Crinetics Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Crinetics Pharmaceuticals compare to Zoetis?

Zoetis (NYSE:ZTS) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

92.8% of Zoetis shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 0.2% of Zoetis shares are held by company insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Zoetis currently has a consensus price target of $107.43, suggesting a potential upside of 38.71%. Crinetics Pharmaceuticals has a consensus price target of $81.00, suggesting a potential downside of 4.53%. Given Zoetis' stronger consensus rating and higher probable upside, analysts clearly believe Zoetis is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	2 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24

Zoetis has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.12, meaning that its share price is 88% less volatile than the broader market.

Zoetis has a net margin of 27.49% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Zoetis' return on equity of 74.89% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zoetis	27.49%	74.89%	18.59%
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

In the previous week, Zoetis had 3 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 13 mentions for Zoetis and 10 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 1.56 beat Zoetis' score of 1.08 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zoetis	9 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Crinetics Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Zoetis has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$9.47B	3.38	$2.67B	$6.07	12.76
Crinetics Pharmaceuticals	$7.70M	1,168.70	-$465.32M	-$5.04	N/A

Summary

Zoetis beats Crinetics Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Crinetics Pharmaceuticals compare to Viatris?

Viatris (NASDAQ:VTRS) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Viatris has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.12, meaning that its stock price is 88% less volatile than the broader market.

In the previous week, Crinetics Pharmaceuticals had 8 more articles in the media than Viatris. MarketBeat recorded 10 mentions for Crinetics Pharmaceuticals and 2 mentions for Viatris. Crinetics Pharmaceuticals' average media sentiment score of 1.56 beat Viatris' score of 1.15 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Crinetics Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

79.9% of Viatris shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 0.3% of Viatris shares are held by insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Viatris presently has a consensus target price of $17.50, suggesting a potential upside of 7.10%. Crinetics Pharmaceuticals has a consensus target price of $81.00, suggesting a potential downside of 4.53%. Given Viatris' stronger consensus rating and higher possible upside, analysts clearly believe Viatris is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24

Crinetics Pharmaceuticals has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.31	-$3.51B	-$0.36	N/A
Crinetics Pharmaceuticals	$7.70M	1,168.70	-$465.32M	-$5.04	N/A

Viatris has a net margin of -2.79% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Viatris' return on equity of 20.02% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.79%	20.02%	8.02%
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

Summary

Viatris beats Crinetics Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Crinetics Pharmaceuticals compare to Jazz Pharmaceuticals?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 4.1% of Jazz Pharmaceuticals shares are held by company insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Jazz Pharmaceuticals had 32 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 42 mentions for Jazz Pharmaceuticals and 10 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 1.56 beat Jazz Pharmaceuticals' score of 0.35 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	11 Very Positive mention(s)	9 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Crinetics Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Jazz Pharmaceuticals has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.27B	3.72	-$356.15M	$14.50	16.86
Crinetics Pharmaceuticals	$7.70M	1,168.70	-$465.32M	-$5.04	N/A

Jazz Pharmaceuticals currently has a consensus price target of $285.44, suggesting a potential upside of 16.73%. Crinetics Pharmaceuticals has a consensus price target of $81.00, suggesting a potential downside of 4.53%. Given Jazz Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Jazz Pharmaceuticals is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	3.00
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24

Jazz Pharmaceuticals has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.12, meaning that its stock price is 88% less volatile than the broader market.

Jazz Pharmaceuticals has a net margin of 20.45% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Jazz Pharmaceuticals' return on equity of 33.97% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	20.45%	33.97%	13.02%
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

Summary

Jazz Pharmaceuticals beats Crinetics Pharmaceuticals on 14 of the 17 factors compared between the two stocks.

How does Crinetics Pharmaceuticals compare to Neurocrine Biosciences?

Neurocrine Biosciences (NASDAQ:NBIX) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

In the previous week, Neurocrine Biosciences had 11 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 21 mentions for Neurocrine Biosciences and 10 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 1.56 beat Neurocrine Biosciences' score of 1.34 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	18 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Crinetics Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 4.6% of Neurocrine Biosciences shares are held by company insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Neurocrine Biosciences has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.12, indicating that its stock price is 88% less volatile than the broader market.

Neurocrine Biosciences presently has a consensus price target of $200.86, suggesting a potential upside of 30.38%. Crinetics Pharmaceuticals has a consensus price target of $81.00, suggesting a potential downside of 4.53%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Neurocrine Biosciences is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.88
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24

Neurocrine Biosciences has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$2.86B	5.47	$478.60M	$6.82	22.59
Crinetics Pharmaceuticals	$7.70M	1,168.70	-$465.32M	-$5.04	N/A

Neurocrine Biosciences has a net margin of 20.91% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Neurocrine Biosciences' return on equity of 22.43% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	20.91%	22.43%	15.64%
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

Summary

Neurocrine Biosciences beats Crinetics Pharmaceuticals on 14 of the 17 factors compared between the two stocks.

Get Crinetics Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRNX vs. The Competition

Export

Metric	Crinetics Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.00B	$12.17B	$7.23B	$12.95B
Dividend Yield	N/A	2.62%	2.54%	11.02%
P/E Ratio	-16.83	787.65	273.45	25.45
Price / Sales	1,168.70	763.23	624.60	95.63
Price / Cash	N/A	95.73	79.29	54.21
Price / Book	7.55	11.97	12.97	6.14
Net Income	-$465.32M	$2.83B	$3.48B	$348.86M
7 Day Performance	0.18%	0.40%	0.13%	-0.80%
1 Month Performance	1.14%	6.25%	8.37%	5.56%
1 Year Performance	173.77%	5.95%	24.55%	15.57%

Crinetics Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRNX Crinetics Pharmaceuticals	1.6775 of 5 stars	$84.84 0.0%	$81.00 -4.5%	+176.8%	$9.00B	$7.70M	N/A	210	Positive News
RPRX Royalty Pharma	3.6731 of 5 stars	$59.45 +1.5%	$60.86 +2.4%	+70.8%	$33.74B	$2.54B	41.00	80
ZTS Zoetis	4.9335 of 5 stars	$72.71 -1.5%	$109.62 +50.8%	-50.0%	$30.49B	$9.53B	11.98	14,500	Analyst Forecast
VTRS Viatris	3.4522 of 5 stars	$16.23 flat	$17.50 +7.8%	+57.0%	$18.64B	$14.30B	N/A	30,000	Positive News Analyst Upgrade
JAZZ Jazz Pharmaceuticals	4.1607 of 5 stars	$248.36 +1.4%	$272.89 +9.9%	+93.9%	$15.90B	$4.27B	17.13	2,890	Trending News Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRNX) was last updated on 8/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Crinetics Pharmaceuticals (CRNX) Competitors

CRNX vs. RPRX, ZTS, VTRS, JAZZ, and NBIX

How does Crinetics Pharmaceuticals compare to Royalty Pharma?

Summary

How does Crinetics Pharmaceuticals compare to Zoetis?

Summary

How does Crinetics Pharmaceuticals compare to Viatris?

Summary

How does Crinetics Pharmaceuticals compare to Jazz Pharmaceuticals?

Summary

How does Crinetics Pharmaceuticals compare to Neurocrine Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRNX vs. The Competition

Crinetics Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Crinetics Pharmaceuticals (CRNX) Competitors

CRNX vs. RPRX, ZTS, VTRS, JAZZ, and NBIX

How does Crinetics Pharmaceuticals compare to Royalty Pharma?

Which has stronger earnings and valuation, RPRX or CRNX?

Which has more risk and volatility, RPRX or CRNX?

Is RPRX or CRNX more profitable?

Do analysts prefer RPRX or CRNX?

Does the media favor RPRX or CRNX?

Do insiders and institutionals hold more shares of RPRX or CRNX?

Summary

How does Crinetics Pharmaceuticals compare to Zoetis?

Do insiders & institutionals hold more shares of ZTS or CRNX?

Do analysts rate ZTS or CRNX?

Which has more volatility and risk, ZTS or CRNX?

Is ZTS or CRNX more profitable?

Does the media favor ZTS or CRNX?

Which has better valuation and earnings, ZTS or CRNX?

Summary

How does Crinetics Pharmaceuticals compare to Viatris?

Which has more volatility & risk, VTRS or CRNX?

Does the media favor VTRS or CRNX?

Do insiders and institutionals hold more shares of VTRS or CRNX?

Do analysts rate VTRS or CRNX?

Which has higher earnings & valuation, VTRS or CRNX?

Is VTRS or CRNX more profitable?

Summary

How does Crinetics Pharmaceuticals compare to Jazz Pharmaceuticals?

Do institutionals & insiders hold more shares of JAZZ or CRNX?

Does the media refer more to JAZZ or CRNX?

Which has preferable valuation & earnings, JAZZ or CRNX?

Do analysts rate JAZZ or CRNX?

Which has more risk and volatility, JAZZ or CRNX?

Is JAZZ or CRNX more profitable?

Summary

How does Crinetics Pharmaceuticals compare to Neurocrine Biosciences?

Does the media favor NBIX or CRNX?

Do insiders and institutionals hold more shares of NBIX or CRNX?

Which has more volatility and risk, NBIX or CRNX?

Do analysts prefer NBIX or CRNX?

Which has better valuation & earnings, NBIX or CRNX?

Is NBIX or CRNX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRNX vs. The Competition

Crinetics Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools